Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ZLAB

Zai Lab Limited ADR

Apr 26 • 04:00PM ET

15.91

Dollar change +0.17
Percentage change 1.08	%

Healthcare • Biotechnology • China • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-3.46	Insider Own	0.54%	Shs Outstand	98.72M	Perf Week	13.08%
Market Cap	1.57B	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-9.38%	Shs Float	98.19M	Perf Month	-1.73%
Income	-334.62M	PEG	-	EPS next Q	-0.51	Inst Own	42.00%	Short Float	4.15%	Perf Quarter	-30.04%
Sales	266.72M	P/S	5.89	EPS this Y	7.60%	Inst Trans	-2.01%	Short Ratio	6.34	Perf Half Y	-33.87%
Book/sh	8.19	P/B	1.94	EPS next Y	56.67%	ROA	-29.66%	Short Interest	4.08M	Perf Year	-54.11%
Cash/sh	8.17	P/C	1.95	EPS next 5Y	-	ROE	-36.34%	52W Range	13.48 - 39.50	Perf YTD	-41.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.93%	ROI	-41.61%	52W High	-59.72%	Beta	1.11
Dividend TTM	-	Quick Ratio	4.41	Sales past 5Y	2095.12%	Gross Margin	64.08%	52W Low	18.03%	ATR (14)	0.77
Dividend Ex-Date	-	Current Ratio	4.63	EPS Y/Y TTM	25.17%	Oper. Margin	-141.19%	RSI (14)	50.11	Volatility	4.22% 4.17%
Employees	2175	Debt/Eq	0.02	Sales Y/Y TTM	24.03%	Profit Margin	-125.46%	Recom	1.15	Target Price	51.69
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-52.98%	Payout	-	Rel Volume	0.57	Prev Close	15.74
Sales Surprise	-8.76%	EPS Surprise	-90.47%	Sales Q/Q	5.16%	Earnings	May 08 AMC	Avg Volume	642.98K	Price	15.91
SMA20	4.66%	SMA50	-9.58%	SMA200	-32.89%	Trades		Volume	364,581	Change	1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Morgan Stanley	Overweight	$47.50
Aug-10-23	Initiated	Cantor Fitzgerald	Overweight	$70
Jan-21-22	Initiated	Macquarie	Outperform	$64
Oct-12-21	Initiated	Bernstein	Mkt Perform
Apr-28-20	Initiated	Goldman	Buy
Apr-15-20	Initiated	Guggenheim	Buy	$75
Jul-12-19	Initiated	BofA/Merrill	Buy
Jul-05-19	Initiated	Macquarie	Outperform
Jan-29-19	Initiated	Credit Suisse	Outperform
Nov-21-18	Initiated	Jefferies	Buy
Jun-21-18	Resumed	Leerink Partners	Outperform	$43
Feb-14-18	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Initiated	Leerink Partners	Outperform	$42
Oct-16-17	Initiated	JP Morgan	Neutral	$32

Show Previous Ratings

Apr-15-24 07:30AM	Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024 (Business Wire)
Apr-11-24 07:30AM	Zai Lab Statement on Executive Management Teams Agreement on Share Activities (Business Wire)
Apr-02-24 07:30AM	Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs (Business Wire)
Apr-01-24 07:30AM	Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... (Business Wire)
Mar-27-24 09:29AM	Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
04:30PM	Loading…
Mar-20-24 04:30PM	Shhh! 7 Small-Cap Stocks That Can Double by 2025 (InvestorPlace) -5.80%
Mar-19-24 07:01PM	Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB) (GuruFocus.com)
Mar-13-24 07:05PM	Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors (Business Wire)
Mar-06-24 04:01PM	Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) (Business Wire)
07:30AM	Zai Lab Announces Participation in March Investor Conference (Business Wire)
Mar-01-24 10:12AM	argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 08:51AM	Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:38PM	Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results (GuruFocus.com) +7.15%
04:05PM	Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates (Business Wire)
Feb-25-24 09:32PM	Qiming Venture Partners Becomes a UN PRI Signatory (PR Newswire)
04:15PM	Loading…
Jan-25-24 04:15PM	Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024 (Business Wire)
Jan-10-24 05:12PM	Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC (Business Wire)
Jan-04-24 07:02PM	Zai Lab Ltd Chairperson & CEO Ying Du Sells 8,380 Shares (GuruFocus.com)
Dec-22-23 12:00PM	What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock (Zacks)
Dec-19-23 07:30AM	Zai Lab Announces Participation in January Investor Conference (Business Wire)
Dec-13-23 08:53AM	Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA in China's National Reimbursement Drug List (GlobeNewswire) +11.85%
Dec-12-23 11:10PM	Zai Lab Announces the First Listing of VYVGART (efgartigimod alfa injection) and Other Updates in Chinas National Reimbursement Drug List (Business Wire)
Nov-23-23 09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-09-23 02:39PM	Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call Transcript (Insider Monkey) -6.16%
Nov-07-23 04:05PM	Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-26-23 07:30AM	Zai Lab Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-18-23 07:30AM	Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 (GlobeNewswire)
Oct-17-23 08:25AM	Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains? (Zacks)
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Sep-21-23 04:48PM	Betting Big: 3 Tech Stocks Primed for a Breakout (InvestorPlace) -5.55%
07:30AM	Loading…
Sep-18-23 07:30AM	Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China (GlobeNewswire)
Sep-05-23 11:16AM	Why Shares of Zai Lab Limited Were Jumping on Tuesday (Motley Fool) +9.73%
09:23AM	Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals (Zacks)
Aug-31-23 09:16AM	Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug (Zacks)
Aug-30-23 07:30AM	Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China (GlobeNewswire) +11.39%
Aug-29-23 07:38AM	Zai Lab Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-10-23 10:12AM	Penn downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 04:05PM	Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +5.32%
Jul-20-23 07:30AM	Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023 (GlobeNewswire)
Jul-19-23 07:30AM	JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients (GlobeNewswire)
Jul-17-23 01:03AM	Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Jul-14-23 07:30AM	Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer (GlobeNewswire)
Jul-10-23 07:30AM	Zai Lab Announces Acceptance by Chinas NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis (GlobeNewswire)
Jul-06-23 04:05PM	Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer (GlobeNewswire) -5.94%
Jun-30-23 11:20AM	UPDATE 2-Argenx's and Zai Lab's U.S. shares rise after muscle-weakening disease drug gets China's approval (Reuters)
09:22AM	Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China (GlobeNewswire)
Jun-28-23 07:30AM	Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by Chinas NMPA (GlobeNewswire)
Jun-12-23 08:56AM	Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation (Simply Wall St.)
Jun-07-23 11:05AM	Why Shares of Zai Lab Are Dropping Wednesday (Motley Fool) -14.55%
Jun-06-23 08:05AM	Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (GlobeNewswire) -5.33%
Jun-01-23 04:03PM	Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting (GlobeNewswire)
May-25-23 07:30AM	Zai Lab Announces Participation in June Investor Conferences (GlobeNewswire) -5.91%
May-24-23 08:01AM	12 Best Chinese Stocks to Buy Now (Insider Monkey)
May-22-23 11:11AM	Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today (Motley Fool) +8.70%
May-18-23 07:30AM	Zai Lab Announces That Repotrectinib Granted Priority Review by Chinas NMPA (GlobeNewswire) -6.06%
May-15-23 02:57PM	Investors push Zai Lab (NASDAQ:ZLAB) 9.3% lower this week, company's increasing losses might be to blame (Simply Wall St.)
May-10-23 11:53AM	Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up (Zacks) +6.08%
May-09-23 04:01PM	Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-03-23 09:58PM	Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength? (Zacks)
Apr-27-23 07:30AM	Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology (GlobeNewswire)
Apr-26-23 10:25AM	Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-20-23 07:30AM	Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023 (GlobeNewswire)
Apr-18-23 01:55PM	Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) (Simply Wall St.)
Apr-14-23 03:32AM	Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Apr-11-23 08:03AM	Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting (GlobeNewswire) +11.38%
Mar-26-23 07:45AM	1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off (Motley Fool)
Mar-20-23 06:35AM	Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia (GlobeNewswire) -10.75%
Mar-17-23 07:19AM	Loss-Making Zai Lab Limited (NASDAQ:ZLAB) Expected To Breakeven In The Medium-Term (Simply Wall St.)
06:59AM	2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years (Motley Fool)
Mar-10-23 06:55AM	2 Stocks That Could Rebound and Rise 30% or More in 2023 (Motley Fool)
Mar-08-23 09:06AM	Zai Lab Limited (NASDAQ:ZLAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-06-23 09:55AM	Does Zai Lab Limited Unsponsored ADR (ZLAB) Have the Potential to Rally 115.25% as Wall Street Analysts Expect? (Zacks)
08:30AM	2 Growth Stocks With Incredible Potential in the Next 5 Years (Motley Fool)
Mar-03-23 12:55PM	10 High Growth Chinese Stocks To Buy (Insider Monkey) +10.78%
Mar-01-23 04:01PM	Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates (GlobeNewswire) +8.69%
Feb-28-23 07:30AM	Zai Lab Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-22-23 04:30PM	Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress (GlobeNewswire)
07:30AM	Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA (GlobeNewswire)
Feb-09-23 07:30AM	Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023 (GlobeNewswire)
Feb-07-23 05:36AM	Is There An Opportunity With Zai Lab Limited's (NASDAQ:ZLAB) 35% Undervaluation? (Simply Wall St.)
Jan-31-23 07:30AM	Zai Lab Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-30-23 07:30AM	Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by Chinas NMPA (GlobeNewswire)
Jan-27-23 02:56PM	Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride (Investor's Business Daily)
Jan-18-23 07:49AM	Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in Chinas National Reimbursement Drug List (GlobeNewswire)
Jan-16-23 02:18AM	Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-09-23 07:30AM	Zai Lab Appoints Michel Vounatsos To Its Board of Directors (GlobeNewswire) -9.02%
Jan-05-23 03:50PM	Why Shares of Zai Lab Soared This Week (Motley Fool) +41.80%
10:21AM	Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients (Benzinga)
10:19AM	This Good News on Cancer Sent 2 Nasdaq Stocks Soaring (Motley Fool)
08:57AM	Novocure, Zai shares rally after lung-cancer treatment meets primary endpoint in study (MarketWatch)
07:34AM	Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint (GlobeNewswire)
Jan-03-23 08:30AM	Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development (GlobeNewswire)
Jan-01-23 08:13AM	Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth (Simply Wall St.)
Dec-20-22 07:30AM	Zai Lab Announces Participation in January Investor Conferences (GlobeNewswire)
Dec-19-22 08:38AM	Top 15 Chinese Companies on NASDAQ (Insider Monkey) -7.73%
Dec-15-22 04:05PM	Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary (GlobeNewswire) -6.27%
Dec-05-22 06:10PM	Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire) -7.82%
Nov-12-22 08:05AM	Zai Lab Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-09-22 04:01PM	Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates (GlobeNewswire)

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reinhart Harald	See Remarks	Apr 04 '24	Sale	15.67	2,105	32,992	51,800	Apr 05 05:48 PM
Smiley Joshua L	See Remarks	Apr 04 '24	Sale	15.67	1,988	31,158	28,684	Apr 05 05:48 PM
Amado Rafael	See Remarks	Apr 04 '24	Sale	15.67	1,952	30,594	23,532	Apr 05 05:47 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 04 '24	Sale	15.67	1,244	19,497	26,408	Apr 05 05:48 PM
Chen Yajing	Chief Financial Officer	Apr 04 '24	Sale	15.67	845	13,244	9,618	Apr 05 05:47 PM
Smiley Joshua L	See Remarks	Apr 03 '24	Option Exercise	15.90	7,145	113,606	30,672	Apr 05 05:48 PM
Amado Rafael	See Remarks	Apr 03 '24	Option Exercise	15.90	5,391	85,717	25,484	Apr 05 05:47 PM
Reinhart Harald	See Remarks	Apr 03 '24	Option Exercise	15.90	5,270	83,793	53,905	Apr 05 05:48 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 03 '24	Option Exercise	15.90	5,031	79,993	27,652	Apr 05 05:48 PM
Chen Yajing	Chief Financial Officer	Apr 03 '24	Option Exercise	15.90	2,500	39,750	10,463	Apr 05 05:47 PM
Du Ying	Chairperson & CEO	Apr 02 '24	Sale	16.15	5,787	93,466	1,107,972	Apr 03 09:44 PM
Reinhart Harald	See Remarks	Apr 02 '24	Sale	16.15	1,773	28,636	48,635	Apr 03 09:45 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 02 '24	Sale	16.15	885	14,294	22,621	Apr 03 09:54 PM
Chen Yajing	Chief Financial Officer	Apr 02 '24	Sale	16.15	519	8,382	7,963	Apr 03 09:44 PM
Du Ying	Chairperson & CEO	Apr 01 '24	Option Exercise	16.72	14,200	237,424	1,113,759	Apr 03 09:44 PM
Reinhart Harald	See Remarks	Apr 01 '24	Option Exercise	16.72	4,348	72,699	50,408	Apr 03 09:45 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 01 '24	Option Exercise	16.72	3,501	58,537	23,506	Apr 03 09:54 PM
Chen Yajing	Chief Financial Officer	Apr 01 '24	Option Exercise	16.72	1,500	25,080	8,482	Apr 03 09:44 PM
Edmondson Frazor Titus III	Chief Legal Officer	Mar 15 '24	Sale	18.71	10,000	187,127	20,005	Mar 19 04:12 PM
Amado Rafael	See Remarks	Mar 15 '24	Sale	18.86	2,544	47,980	20,093	Mar 19 04:12 PM
Smiley Joshua L	See Remarks	Mar 01 '24	Buy	20.83	3,000	62,490	23,527	Mar 04 04:28 PM
Du Ying	Chairperson & CEO	Jan 03 '24	Sale	26.12	8,380	218,902	1,133,450	Jan 03 07:25 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jan 03 '24	Sale	26.12	4,803	125,464	30,005	Jan 03 07:25 PM
Reinhart Harald	See Remarks	Jan 03 '24	Sale	26.12	4,803	125,464	46,060	Jan 03 07:25 PM
Amado Rafael	See Remarks	Jan 02 '24	Sale	26.30	19,363	509,169	22,637	Jan 03 07:26 PM
Smiley Joshua L	See Remarks	Dec 14 '23	Buy	29.90	4,000	119,600	20,527	Dec 18 05:08 PM
Smiley Joshua L	See Remarks	Nov 16 '23	Buy	26.93	5,000	134,650	16,527	Nov 16 06:04 PM
Chen Yajing	Chief Financial Officer	Nov 02 '23	Sale	25.23	165	4,163	6,982	Nov 03 04:44 PM
Du Ying	Chairperson & CEO	Jun 23 '23	Option Exercise	25.30	58,800	1,487,640	1,055,913	Jun 26 04:06 PM
Reinhart Harald	See Remarks	Jun 23 '23	Option Exercise	25.30	18,250	461,725	40,497	Jun 26 04:07 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jun 23 '23	Option Exercise	25.30	14,600	369,380	36,547	Jun 26 04:05 PM

Open in Screener

ALLO

Allogene Therapeutics Inc

Apr 26 • 04:00PM ET

2.89

Dollar change +0.04
Percentage change 1.23	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ALLO Allogene Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWM VB VBK IWN IBB LABU VHT VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.09	Insider Own	38.07%	Shs Outstand	170.72M	Perf Week	-16.71%
Market Cap	493.38M	Forward P/E	-	EPS next Y	-1.55	Insider Trans	-0.03%	Shs Float	105.73M	Perf Month	-35.20%
Income	-323.79M	PEG	-	EPS next Q	-0.41	Inst Own	60.20%	Short Float	29.66%	Perf Quarter	-10.80%
Sales	0.16M	P/S	3083.63	EPS this Y	21.14%	Inst Trans	5.02%	Short Ratio	13.69	Perf Half Y	8.65%
Book/sh	3.47	P/B	0.83	EPS next Y	5.90%	ROA	-	Short Interest	31.36M	Perf Year	-46.78%
Cash/sh	2.63	P/C	1.10	EPS next 5Y	1.00%	ROE	-	52W Range	2.23 - 6.89	Perf YTD	-9.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.18%	ROI	-48.10%	52W High	-58.06%	Beta	0.89
Dividend TTM	-	Quick Ratio	12.58	Sales past 5Y	-27.79%	Gross Margin	-7505.91%	52W Low	29.60%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	12.58	EPS Y/Y TTM	10.07%	Oper. Margin	-196516.88%	RSI (14)	21.63	Volatility	7.43% 5.78%
Employees	-	Debt/Eq	0.19	Sales Y/Y TTM	-24.70%	Profit Margin	-202366.25%	Recom	1.69	Target Price	12.08
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	22.55%	Payout	-	Rel Volume	1.07	Prev Close	2.86
Sales Surprise	-4.55%	EPS Surprise	-13.13%	Sales Q/Q	-55.32%	Earnings	Mar 14 AMC	Avg Volume	2.29M	Price	2.89
SMA20	-23.06%	SMA50	-33.85%	SMA200	-22.71%	Trades		Volume	2,452,076	Change	1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Stifel	Buy → Hold	$44 → $18
Oct-08-21	Downgrade	Goldman	Buy → Neutral	$71 → $20
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy	$53
May-20-21	Upgrade	Truist	Hold → Buy	$34 → $41
May-14-21	Initiated	B. Riley Securities	Buy	$52

Show Previous Ratings

Apr-26-24 10:32AM	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development (MT Newswires)
08:30AM	Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma (GlobeNewswire)
Apr-24-24 10:01AM	Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -9.79%
Apr-11-24 02:45PM	3 Meme Stocks to Sell and Replace With Meme Coins (InvestorPlace)
Apr-09-24 08:30AM	Allogene Therapeutics Announces Q2 Investor Conference Participation (GlobeNewswire)
08:46AM	Loading…
Apr-08-24 08:46AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Mar-16-24 04:35PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 09:32AM	Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss (Zacks)
07:04AM	Q4 2023 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.89%
05:34PM	Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ... (GuruFocus.com)
05:15PM	Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Mar-13-24 12:15PM	Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology (Zacks)
08:50AM	Loading…
Mar-12-24 08:50AM	Allogene taps Arbor in pursuit of off-the-shelf CAR-T therapies for autoimmune disease (BioPharma Dive)
08:30AM	Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease (GlobeNewswire)
Mar-05-24 09:55AM	Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update (GlobeNewswire)
Feb-28-24 08:30AM	Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-16-24 08:30AM	Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia (GlobeNewswire)
Jan-16-24 04:05PM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-12-24 08:34AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Jan-05-24 12:52PM	Allogene (ALLO) Down 20% on Strategic Changes in Pipeline (Zacks) -14.01%
08:25AM	UPDATE 2-Allogene to cut 22% of its workforce (Reuters)
08:13AM	Allogene to cut 22% of its workforce (Reuters)
Jan-04-24 04:15PM	Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
04:05PM	Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
11:05AM	Allogene to shift strategy in bid to reposition CAR-T (BioPharma Dive)
Jan-03-24 04:05PM	Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.01%
12:00PM	Loading…
Dec-09-23 12:00PM	Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Dec-01-23 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conference (GlobeNewswire) +7.23%
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-10-23 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-03-23 12:15PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript (Insider Monkey) +17.85%
12:00PM	Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak and Dagger Technologies at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
12:00PM	Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
10:15AM	Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-02-23 07:33PM	Allogene Therapeutics Inc (ALLO) Reports Q3 2023 Financial Results (GuruFocus.com)
04:12PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
09:00AM	Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Oct-30-23 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +9.09%
Oct-26-23 08:30AM	Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-16-23 09:26AM	The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics (Zacks)
08:30AM	Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer (GlobeNewswire)
Sep-27-23 09:09AM	Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-25-23 08:45AM	JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment (Investing.com)
Sep-05-23 08:30AM	Allogene Therapeutics Announces Participation in September Investor Conference (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-14-23 08:30AM	Allogene Therapeutics Appoints Earl Douglas as General Counsel (GlobeNewswire)
Aug-03-23 11:20AM	Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss (Zacks) +9.59%
Aug-02-23 05:25PM	Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Allogene Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:02PM	Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
10:41AM	Too Cheap to Ignore: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money (TipRanks)
Jul-26-23 08:30AM	Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jun-15-23 09:30AM	Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
Jun-14-23 08:00AM	Allogene Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire) -12.54%
Jun-09-23 06:25PM	Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-03-23 09:00AM	Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-02-23 11:31AM	Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound? (Zacks) +5.45%
May-31-23 12:02PM	Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal (Zacks)
10:46AM	J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH (Zacks)
May-29-23 07:48AM	AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal (Zacks)
May-26-23 10:51AM	Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails (Zacks)
09:55AM	Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High? (Zacks)
08:23AM	PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study (Zacks)
May-25-23 03:16PM	Immutep (IMMP) Up on Initial Data From Lung Cancer Study (Zacks)
May-24-23 11:37AM	Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data (Zacks) -5.95%
08:30AM	Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
08:14AM	INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up (Zacks)
May-22-23 08:16AM	We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-19-23 11:16AM	PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study (Zacks)
10:24AM	AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease (Zacks)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace)
12:45PM	MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study (Zacks)
11:15AM	Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing (Zacks)
May-17-23 02:19PM	Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag (Zacks)
11:21AM	PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up (Zacks)
11:13AM	Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag (Zacks)
May-16-23 09:31AM	Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases (Zacks) -9.05%
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
10:04AM	Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why (Zacks)
May-11-23 12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
11:50AM	Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
09:44AM	Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates (Zacks)
09:33AM	TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines (Zacks)
07:44AM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow (Zacks)
May-10-23 09:55AM	Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 184.59%: Read This Before Placing a Bet (Zacks)
May-09-23 10:40AM	Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates (Zacks)
May-08-23 10:04AM	Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises (Zacks)
May-05-23 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update (Zacks)
May-04-23 03:29PM	Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance (Zacks) +12.76%
12:04PM	Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y (Zacks)

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Jan 30 '24	Buy	3.60	190	683	819,590	Mar 06 09:52 PM
MESSEMER DEBORAH M.	Director	Dec 18 '23	Sale	2.70	18,640	50,317	62,456	Dec 20 04:26 PM
Mayo Stephen	Director	Aug 07 '23	Sale	4.29	10,000	42,855	25,328	Aug 09 04:07 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ZLAB

Zai Lab Limited ADR

ALLO

Allogene Therapeutics Inc

Upgrade your FINVIZ experience